Elevar Therapeutics Joins Benefactors Council of Blue Faery, Leading Hepatocellular Carcinoma Advocacy Group
September 19, 2023 09:00 ET
|
Elevar Therapeutics
FORT LEE, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
Elevar Therapeutics to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib in Combination with Camrelizumab in Unresectable Hepatocellular Carcinoma (uHCC)
August 03, 2023 09:00 ET
|
Elevar Therapeutics
FORT LEE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
Elevar Therapeutics Announces Publication of Phase 3 CARES 310 Study Results in The Lancet
July 24, 2023 21:39 ET
|
Elevar Therapeutics
FORT LEE, N.J., July 24, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
Oncologists Global Market Report 2023: Rising Prevalence of Cancer Fuels the Sector
May 25, 2023 09:53 ET
|
Research and Markets
Dublin, May 25, 2023 (GLOBE NEWSWIRE) -- The "Oncologists Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers and...
Elevar Therapeutics Submits New Drug Application to FDA for Combination of Rivoceranib and Camrelizumab as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma
May 17, 2023 07:00 ET
|
Elevar Therapeutics
FORT LEE, N.J., May 17, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a wholly owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
Liver Cancer Diagnostics Market to Observe Utmost Growth of USD 12,445.57 Million by 2030, Size, Share, Trends, Demand, Industry Growth and Key Player Analysis
May 11, 2023 04:30 ET
|
Data Bridge Market Research
SYDNEY, May 11, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research has unveiled a new report called "Liver Cancer Diagnostics Market" which provides an in-depth exploration of growth strategies,...
Elevar Therapeutics Presents AACR 2023 Poster Demonstrating Rivoceranib as Most Selective VEGFR-2 Inhibitor When Compared to Other TKIs With Known Activity Against VEGFR-2
April 18, 2023 09:00 ET
|
Elevar Therapeutics
ORLANDO, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
Interventional Oncology Market is Expected to Reach $2.9 billion | MarketsandMarkets.
April 12, 2023 09:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, April 12, 2023 (GLOBE NEWSWIRE) -- The interventional oncology industry is expected to experience significant growth in the coming years, as new technologies and treatments are developed...
Global Interventional Oncology Devices Market Report 2023: Players Include Boston Scientific, Medtronic, Terumo, and Philips Volcano
March 30, 2023 10:18 ET
|
Research and Markets
Dublin, March 30, 2023 (GLOBE NEWSWIRE) -- The "Interventional Oncology Devices Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides...
Core Biopsy Needles Market to Rise at 5.5% CAGR during Forecast Period 2023-2030, Data By Contrive Datum Insights
March 28, 2023 10:23 ET
|
Contrive Datum Insights Pvt Ltd
Farmington, March 28, 2023 (GLOBE NEWSWIRE) -- The Global Core Biopsy Needles Market Size Is Projected To Grow At A CAGR Of 5.5% During The Forecast Period 2022-2030. A biopsy is a surgical...